About Nkarta, Inc.
https://www.nkartatx.comNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
CEO
Paul J. Hastings
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.81M
Value:$22.37M
TANG CAPITAL MANAGEMENT LLC
Shares:7.06M
Value:$14.61M
BLACKROCK INC.
Shares:4.06M
Value:$8.4M
Summary
Showing Top 3 of 133
About Nkarta, Inc.
https://www.nkartatx.comNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $27.29M ▲ | $-21.71M ▲ | 0% | $-0.29 ▲ | $-19.41M ▲ |
| Q2-2025 | $0 | $27.19M ▼ | $-22.98M ▲ | 0% | $-0.31 ▲ | $-24.86M ▲ |
| Q1-2025 | $0 | $36.56M ▲ | $-31.98M ▼ | 0% | $-0.43 ▼ | $-29.16M ▼ |
| Q4-2024 | $0 | $30.92M ▼ | $-25.93M ▲ | 0% | $-0.35 ▲ | $-28.64M ▲ |
| Q3-2024 | $0 | $33.79M | $-28.34M | 0% | $-0.39 | $-31.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $282.33M ▼ | $427.24M ▼ | $89.34M ▼ | $337.9M ▼ |
| Q2-2025 | $289.69M ▲ | $448.31M ▼ | $90.64M ▼ | $357.67M ▼ |
| Q1-2025 | $265.51M ▼ | $470.61M ▼ | $91.8M ▼ | $378.81M ▼ |
| Q4-2024 | $267.35M ▼ | $501.2M ▼ | $93.23M ▼ | $407.98M ▼ |
| Q3-2024 | $283.06M | $532.03M | $101.16M | $430.87M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-21.71M ▲ | $-18.69M ▲ | $25.39M ▲ | $0 ▼ | $6.7M ▲ | $-18.68M ▲ |
| Q2-2025 | $-22.98M ▲ | $-18.75M ▲ | $19.49M ▼ | $77K ▲ | $816K ▼ | $-18.89M ▲ |
| Q1-2025 | $-31.98M ▼ | $-29.61M ▼ | $54.34M ▲ | $0 ▼ | $24.73M ▲ | $-30.13M ▼ |
| Q4-2024 | $-25.93M ▲ | $-24.75M ▼ | $-4.52M ▲ | $184K ▲ | $-29.09M ▲ | $-25.85M ▼ |
| Q3-2024 | $-28.34M | $-24.55M | $-38.9M | $2K | $-63.44M | $-25.32M |
CEO
Paul J. Hastings
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.81M
Value:$22.37M
TANG CAPITAL MANAGEMENT LLC
Shares:7.06M
Value:$14.61M
BLACKROCK INC.
Shares:4.06M
Value:$8.4M
Summary
Showing Top 3 of 133